News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Statement on Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices' Recommendation for Pneumococcal Vaccination in Immunocompromised Adults


6/20/2012 12:56:32 PM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP)'s updated recommendation for pneumococcal vaccine as a two vaccine regimen in adults with immunocompromising conditions, functional or anatomic asplenia, cerebral spinal fluid (CSF) leaks or cochlear implants.

Read at BioSpace.com


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES